GERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Group 1: Class Action Details - The class action lawsuit, titled Dabestani v. Geron Corporation, allows purchasers of Geron securities from June 7, 2024, to February 25, 2025, to seek appointment as lead plaintiff by May 12, 2025 [1][5]. - The lawsuit alleges that Geron made false statements about its revenue outlook and growth potential, downplaying risks associated with seasonality and competition [3][4]. - Geron's primary product, Rytelo, is a telomerase inhibitor, which has reportedly struggled to gain market awareness and penetration, impacting its sales performance [2][3]. Group 2: Financial Impact - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and lack of market awareness, leading to a stock price decline of over 32% [4]. - The lawsuit claims that the optimistic projections made by Geron were not reflective of the actual market conditions and challenges faced by the product [3][4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, noted for its significant recoveries in securities fraud cases, including over $2.5 billion in 2024 alone [6]. - The firm has a strong track record in securities class action recoveries, having secured the largest recovery in history at$7.2 billion in the Enron case [6].